July 2025 in “Journal of Investigative Dermatology” Spironolactone can safely lower blood pressure in patients on other blood pressure medications, but may slightly increase the risk of low blood pressure.
66 citations
,
May 2011 in “Dermatologic therapy” This report discusses guidelines for designing alopecia clinical trials that account for variables affecting results, but it presents no new efficacy findings.
This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.
60 citations
,
September 2004 in “Pediatric Dermatology” In this study, a 10-year-old girl developed vitiligo and psoriasis during IFN-alfa treatment for chronic hepatitis B, with neither condition improving after stopping the therapy.
April 2021 in “Journal of Investigative Dermatology” This study found that oral spironolactone improved or maintained hair condition in females with scarring alopecia and female pattern hair loss, with 83% of patients tolerating the treatment well, despite some side effects like hyperkalemia and leg cramps.